Access here is decided by a step edit built around a safety warning, not by comparative efficacy. That single design choice fixes the order of the market.
Most atopic dermatitis is mild and managed topically. The commercially relevant population is the moderate-to-severe, topical-refractory group eligible for systemic therapy, and it is a minority of the diagnosed base. Diagnosis is clinical with no biomarker, and severity is graded by clinical score, so eligibility is defined by an assessment rather than by a test - which makes documentation practice a commercial variable.
The structure of the market follows from payer sequencing. Commercial payers gate the incumbent biologic behind documented topical failure, and gate oral JAK inhibitors behind prior biologic failure. That second gate is driven by a class boxed warning rather than by comparative efficacy, and it places oral agents structurally behind injectables however they perform. Independent value assessment has reached a consistent conclusion, finding the JAK class effective but requiring substantial discounts given the safety position.
The credible competitive threat is not among the agents already on formulary, whose relative positions are largely fixed by that step design, but from a new mechanism entering ahead of the step rather than behind it. Assets targeting OX40 and its ligand, with late-stage readouts arriving now, are the ones capable of changing the sequence rather than joining it.
AXLRx atopic dermatitis reports resolve the systemic-eligible pool, read the step-therapy design that fixes the current order, and assess the pipeline capable of disturbing it.
Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs.
US atopic dermatitis epidemiology — 16.5M adults, the moderate-to-severe pool, and the atopic march that frames the biologic-eligible segment.
Topical-then-biologic step-therapy, JAK black-box PA gates, ICER's dupilumab-aligned and JAK-discount verdicts, and why Dupixent is not IRA-selected.
Dupilumab's 70% share sets the biologic entrenchment bar. The 2022 JAK boxed warning sets a second, harder gate for any oral entrant.
Far less than the prevalence figure suggests. Atopic dermatitis affects roughly 16.5 million US adults and 9.6 million children, but most disease is mild and managed topically. About 40% of affected adults, some 6.6 million, have moderate-to-severe, topical-refractory disease that is eligible for systemic biologics and oral JAK inhibitors. Diagnosis is clinical with no biomarker, and severity is graded by EASI, IGA or SCORAD, so the eligible pool is defined by a severity score rather than by a test.
Because it is what payers built the step edit around. US commercial payers gate dupilumab behind documented topical failure, and gate JAK inhibitors behind prior biologic failure. That sequencing is driven by the 2022 class boxed warning rather than by comparative efficacy, and it puts an oral agent structurally behind an injectable regardless of how it performs. ICER's 2021 review reached a consistent conclusion, finding JAK inhibitors effective but requiring discounts of 35 to 63% given class safety concerns.
The OX40 and OX40L pipeline rather than the current class. Amlitelimab and rocatinlimab, with Phase 3 readouts across 2025 and 2026, target a different mechanism and are the most credible challenge to the installed biologic position. The near-term contest is not between the agents already on formulary, whose relative positions are largely fixed by the step-therapy design, but over whether a new mechanism can enter ahead of that step rather than behind it.
Dupilumab's list price runs about $3,900 to $4,200 per four-week supply, roughly $37,000 net annually, and ICER judged it value-aligned in 2017 at around $31,000 net. It does not appear on any CMS selected-drug list for the 2026 to 2028 negotiation years, though it remains eligible for future cycles. For an entrant, that means the price anchor in this category is stable in the near term and the argument has to be won on access position rather than on a price reset.
A disease-landscape and sizing read that resolves the moderate-to-severe, topical-refractory pool from the headline prevalence; competitive intelligence covering the installed biologic and JAK positions and the OX40 pipeline behind them; and a payer analysis of the step-therapy design, the boxed-warning gate, and the price anchor an entrant will be measured against. Each is scoped to your asset.